Objective Safer and more effective therapies are needed for the treatment of systemic lupus
erythematosus (SLE). B lymphocytes have been shown to play fundamental pathogenic …

To define the cell populations that drive joint inflammation in rheumatoid arthritis (RA), we
applied single-cell RNA sequencing (scRNA-seq), mass cytometry, bulk RNA sequencing (…

Systemic Lupus Erythematosus (SLE) is characterized by B cells lacking IgD and CD27 (double
negative; DN). We show that DN cell expansions reflected a subset of CXCR5 - CD11c + …

Objective Despite wide use of the anti‐CD20 monoclonal antibody rituximab in the treatment
of B cell lymphomas, the mechanism by which it causes B cell depletion remains a subject …

Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is
ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed …

Objective B lymphocyte depletion has recently emerged as a promising approach to the
treatment of systemic lupus erythematosus (SLE). As part of a phase I/II dose‐ranging trial of …

Breach of B cell tolerance is central to the pathogenesis of systemic lupus erythematosus (SLE).
However, how B cell tolerance is subverted in human SLE is poorly understood due to …

Objective Recent data suggest that the reconstituting peripheral B cell compartment after B
cell depletion therapy may be functionally immature, with a preponderance of transitional B …

Transitional cells represent a crucial step in the differentiation and selection of the mature B
cell compartment. Human transitional B cells have previously been variably identified based …

Objective To investigate the hypothesis that proteasome inhibition may have potential in the
treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of …